Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Histone deacetylases (HDACs) are crucial in regulating genes linked to cancer development and progression.
• Histone deacetylase inhibitors (HDACis) represent a novel class of anticancer agents with potential to induce apoptosis and cell cycle arrest in cancer cells.
• While approved for some cancers, HDACis demonstrate limited efficacy as monotherapy for solid tumors and can lead to drug resistance.

Purpose of the Study:

• To review the classification and antitumor mechanisms of HDAC inhibitors.
• To summarize advancements in combining HDAC inhibitors with various anticancer therapies.
• To discuss the future clinical potential and challenges of HDAC inhibitor combination strategies.

Main Methods:

• Literature review on HDAC classification and function.
• Analysis of HDAC inhibitor mechanisms against key cancer processes (cell cycle, apoptosis, angiogenesis, DNA repair, immune response).
• Survey of studies combining HDAC inhibitors with chemotherapy, radiotherapy, phototherapy, targeted therapy, and immunotherapy.

Main Results:

• HDAC inhibitors target fundamental cellular processes critical for cancer cell survival and proliferation.
• Combination therapies involving HDAC inhibitors show synergistic effects with chemotherapy, radiotherapy, phototherapy, targeted therapy, and immunotherapy.
• Evidence suggests that combination strategies can enhance therapeutic efficacy and potentially overcome drug resistance.

Conclusions:

• HDAC inhibitors are valuable in cancer therapy, particularly when used in combination regimens.
• Further clinical studies are needed to optimize HDAC inhibitor combinations for improved antitumor outcomes.
• Combination therapies hold significant promise for overcoming limitations of single-agent HDAC inhibitor treatment in solid tumors.